Abbott Laboratories (ABT) is an interesting player in the Healthcare space, with a focus on Medical Appliances & Equipment. The stock has been active on the tape, currently trading at $54.44, down from yesterday’s close by -1.73%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.
Does this stock stack up well when compared to its peers in the industry space? Let’s take a look. Abbott Laboratories (ABT) currently trades with a market capitalization of $94.75 Billion.
The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ABT, the company currently has $9.68 Billion of cash on the books, which is offset by $221 Million current liabilities. You can get a sense of how sustainable that is by a levered free cash flow of $3.16 Billion over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.65 on a per share basis this quarter. Perhaps, that suggests something about why 71.46% of the outstanding share supply is held by institutional investors.
No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Abbott Laboratories recorded a 52-week high of $55.43. It is now trading 0.99% off that level. The stock is trading $51.25 its 50-day moving average by -3.19%. The stock carved out a 52-week low down at $37.38.
In recent action, Abbott Laboratories (ABT) has made a move of +4.69% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 19.61, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 0.92% with $1.72 Billion sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ABT.